Demeter Biotechnology, operating under the brand name DMT Biotech, specializes in the large-scale production and commercialization of microalgae-based products. Utilizing a proprietary photon carbon smart biomanufacturing platform, the company employs synthetic biology to create specialized algal species. These species are then cultivated using a biological manufacturing system enhanced by artificial intelligence technology.

Demeter's core products include fucoxanthin, EPA (eicosapentaenoic acid), and alternative proteins derived from microalgae. The company aims to capture more than 40% of the global market share in these segments.

Demeter serves a diverse range of clients, including those in the nutraceutical, pharmaceutical, and food industries, who seek sustainable and innovative raw materials. The company operates within the biotechnology and sustainable development markets, focusing on providing eco-friendly solutions.

Demeter's business model revolves around the mass production and sale of high-value microalgae-based raw materials. Revenue is generated through direct sales to industrial clients and partnerships with companies seeking sustainable alternatives to traditional raw materials.

Keywords: microalgae, synthetic biology, AI, fucoxanthin, EPA, alternative protein, biomanufacturing, sustainability, raw materials, biotechnology.